Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.
1 . An isolated multispecific heteromultimer construct comprising:
a first polypeptide construct comprising a first heavy chain polypeptide and a CD3 binding polypeptide construct that binds to a CD3 complex on at least one CD3 expressing cell;
a second polypeptide construct comprising a second heavy chain polypeptide which is different from said first heavy chain polypeptide, and an antigen binding polypeptide construct that binds to a target antigen on at least one B cell; wherein:
at least one of said CD3 binding polypeptide construct and said antigen binding polypeptide construct comprises a single chain Fv region;
said multispecific heteromultimer construct simultaneously engages said at least one B cell and said at least one CD3 expressing cell such that the CD3 expressing cell is activated, thereby inducing killing of the B cell; and
said first and second heavy chain polypeptides form a heterodimeric Fc region comprising a variant immunoglobulin CH3 region comprising at least one amino acid mutation that promotes the formation of said heterodimeric Fc, wherein:
said heterodimeric Fc is formed with stability at least comparable to a native homodimeric Fc, and
said heterodimeric Fc is formed with purity such that when said multispecific heteromultimer construct is expressed in a mammalian cell in an expression product, said expression product comprises at least about 70% of said multispecific heteromultimer, and less than 10% monomers or homodimers of said first or second polypeptide constructs.
2 . The isolated multispecific heteromultimer of claim 1 , wherein said first or second polypeptide construct is devoid of at least one of immunoglobulin light chain, and immunoglobulin first constant (CH1) region.
3 . The isolated multispecific heteromultimer of claim 1 , wherein the heterodimer Fc region comprises a variant CH2 domain or hinge comprising amino acid modifications that prevents functionally effective binding to all the Fcgamma receptors, and/or to complement proteins (C1q complex).
4 . (canceled)
5 . The isolated multispecific heteromultimer of claim 1 , wherein the heterodimer Fc region comprises a variant CH2 domain or hinge comprising amino acid modifications that enhance binding to the FcγRIIb receptor.
6 . An isolated multispecific heteromultimer construct comprising:
a first polypeptide construct comprising a first heavy chain polypeptide and a CD3 binding polypeptide construct that binds to a CD3 complex on at least one CD3 expressing cell;
a second polypeptide construct comprising a second heavy chain polypeptide which is different from said first heavy chain polypeptide, and an antigen binding polypeptide construct that binds to a target antigen on at least one B cell; wherein:
at least one of said CD3 binding polypeptide construct and said antigen binding polypeptide construct optionally comprises a single chain Fv region;
said first and second heavy chain polypeptides form a heterodimeric Fc region comprising a variant immunoglobulin CH3 region comprising at least one amino acid mutation that promotes the formation of said heterodimeric Fc, wherein:
said heterodimeric Fc is formed with stability at least comparable to a native homodimeric Fc, and
said heterodimeric Fc is formed with purity such that when said multispecific heteromultimer construct is coexpressed from a mammalian cell in an expression product, said expression product comprises greater than 70% of said multispecific heteromultimer, and less than 10% monomers or homodimers of said first or second polypeptide constructs; and
said multispecific heteromultimer construct binds said at least one B cell with a valency greater than one, and said multispecific heteromultimer simultaneously engages said at least one B cell and said at least one CD3 expressing cell such that the CD3 expressing cell is activated, thereby inducing killing of the B cell.
7 . (canceled)
8 . (canceled)
9 . The isolated multispecific heteromultimer of claim 1 wherein the heterodimer Fc region comprises a variant CH2 domain comprising amino acid modifications to promote selective binding of a Fcgamma receptor.
10 . (canceled)
11 . (canceled)
12 . The isolated multispecific heteromultimer according to claim 1 , wherein the variant CH3 domain has a melting temperature (Tm) of about 73° C. or greater.
13 . (canceled)
14 . (canceled)
15 . The isolated multispecific heteromultimer according to claim 1 , wherein the heterodimer Fc region is formed with a purity of at least about 90% and/or the Tm is about 75° C.
16 . The isolated multispecific heteromultimer according to claim 1 wherein:
a. the variant CH3 sequence of the first heavy chain polypeptide comprises the amino acid modifications L351Y, F405A, and Y407V, and the variant CH3 sequence of the second transporter polypeptide comprises the amino acid modifications T366L, K392M, and T394W;
b. the variant CH3 sequence of the first heavy chain polypeptide comprises the amino acid modifications L351Y, F405A, and Y407V, and the variant CH3 sequence of the second heavy chain polypeptide comprises the amino acid modifications T366L, K392L, and T394W;
c. the variant CH3 sequence of the first heavy chain polypeptide comprises the amino acid modifications T350V, L351Y, F405A, and Y407V, and the variant CH3 sequence of the second heavy chain polypeptide comprises the amino acid modifications T350V, T366L, K392M, and T394W;
d. the variant CH3 sequence of the first heavy chain polypeptide comprises the amino acid modifications T350V, L351Y, F405A, and Y407V, and the variant CH3 sequence of the second heavy chain polypeptide comprises the amino acid modifications T350V, T366L, K392L, and T394W;
e. the variant CH3 sequence of the first heavy chain polypeptide comprises the amino acid modifications T366L, N390R, K392R, and T394W, and the variant CH3 sequence of the second heavy chain polypeptide comprises the amino acid modifications L351Y, S400E, F405A, and Y407V; or
f. the variant CH3 sequence of the first heavy chain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392R, and T394W, and the variant CH3 sequence of the second heavy chain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405A, and Y407V.
17 . The isolated multispecific heteromultimer of claim 1 wherein the heterodimer Fc is glycosylated, afucosylated, and/or aglycosylated.
18 . (canceled)
19 . (canceled)
20 . The isolated multispecific heteromultimer of claim 1 , wherein said antigen binding polypeptide construct that binds to a target antigen on at least one B cell comprises at least one target antigen binding domain derived from an antibody, a fibronectin, an affibody, anticalin, cysteine knot protein, DARPin, avimer, Kunitz domain or variant or derivative thereof.
21 . The isolated multispecific heteromultimer of claim 20 , wherein said antibody is a heavy chain antibody devoid of light chains.
22 . The isolated multispecific heteromultimer of claim 1 , wherein said antigen binding polypeptide construct comprises at least one CD19 binding domain or at least one CD20 binding domain.
23 .- 34 . (canceled)
35 . The isolated multispecific heteromultimer of claim 1 , wherein said at least one CD3 binding polypeptide construct comprises at least one CD3 binding domain derived from a CD3 specific antibody, a nanobody, fibronectin, affibody, anticalin, cysteine knot protein, DARPin, avimer, Kunitz domain or variant or derivative thereof.
36 . The isolated multispecific heteromultimer of claim 35 , wherein said at least one CD3 binding domain comprises at least one amino acid modification that reduces immunogenicity as compared to a corresponding CD3 binding domain not comprising said modification, or at least one amino acid modification that increases its stability as measured by T m , as compared to a corresponding CD3 binding domain not comprising said modification.
37 . (canceled)
38 . The isolated multispecific heteromultimer of claim 36 , wherein said CD3 specific antibody is a heavy chain antibody devoid of light chains.
39 . (canceled)
40 . The isolated multispecific heteromultimer of claim 1 wherein both of said first and second polypeptide constructs comprise a single-chain Fv polypeptide.
41 . The isolated multispecific heteromultimer of claim 1 wherein at least one of said first and second polypeptide constructs further comprises a single-chain Fab polypeptide.
42 . The isolated multispecific heteromultimer of claim 1 wherein the CD3 expressing cell is a T-cell, and wherein said heteromultimer binds to the T-cell with sufficient affinity and decorates the T cell at sufficient capacity that induces the T-cell to display B cell killing activity when the T cell and the B cell are bridged.
43 . (canceled)
44 . The isolated multispecific heteromultimer of claim 1 where in the CD3 expressing cell is a human cell, or a non-human, mammalian cell.
45 . (canceled)
46 . The isolated multispecific heteromultimer of claim 1 where in the at least one CD3 binding polypeptide construct binds to CD3 constructs across multiple species.
47 . The isolated multispecific heteromultimer of claim 1 wherein the at least one B cell is associated with a cancer, or is an autoimmune reactive cell that is a lymphoid or myeloid cell.
48 . The isolated multispecific heteromultimer of claim 47 wherein the disease is a cancer selected from a carcinoma, a sarcoma, leukaemia, lymphoma and glioma.
49 .- 51 . (canceled)
52 . The isolated multispecific heteromultimer of claim 1 wherein said heteromultimer optionally comprises a linker between the CD3 binding polypeptide construct and said heterodimeric Fc and/or between the antigen binding polypeptide construct and said heterodimeric Fc.
53 . The isolated multispecific heteromultimer of claim 52 , wherein said at least one linker is a polypeptide comprising from about 1 to about 100 amino acids.
54 . A set of expression vectors for expressing the multispecific heteromultimer claim 1 , comprising at least a first DNA sequence encoding said first polypeptide construct and at least a second DNA sequence encoding said second polypeptide construct.
55 . A method of producing an expression product containing a multispecific heteromultimer of claim 1 , in stable mammalian cells, the method comprising:
transfecting at least one mammalian cell with: at least a first DNA sequence encoding said first polypeptide construct and at least a second DNA sequence encoding said second polypeptide construct, such that said at least one first DNA sequence, said at least one second DNA sequence are transfected in said at least one mammalian cell in a pre-determined ratio to generate stable mammalian cells; culturing said stable mammalian cells to produce said expression product comprising said multispecific heteromultimer.
56 .- 57 . (canceled)
58 . A pharmaceutical composition comprising the multispecific heteromultimer of claim 1 , and a suitable excipient.
59 . A process for the production of a pharmaceutical composition of claim 57 , said process comprising:
culturing a host cell under conditions allowing the expression of a heteromultimer of claim 1 ;
recovering the produced heteromultimer from the culture; and
producing the pharmaceutical composition.
60 . (canceled)
61 . A method of treating cancer in a mammal in need thereof, comprising administering to the mammal a composition comprising an effective amount of the heteromultimer of claim 1 , optionally in combination with other pharmaceutically active molecules.
62 .- 67 . (canceled)
68 . A method of treating a cancer non-responsive to at least one of a CD19 lytic antibody, a CD20 lytic antibody and blinatumomab, in a mammal in need thereof, comprising administering to the mammal a composition comprising an effective amount of the heteromultimer of claim 1 .
69 .- 71 . (canceled)
72 . A method of treating an autoimmune condition or an inflammatory condition in a mammal in need thereof, comprising administering to said mammal a composition comprising an effective amount of the heteromultimer of claim 1 .
73 .- 74 . (canceled)
75 . A kit comprising a heteromultimer of claim 1 , and instructions for use thereof.